Third Dose of COVID-19 Vaccine in LTCF Residents

• Status: Not yet recruiting
• Trial end date: 2022-04-15
• Target enrollment: 0
• Participant gender: All

Summary

This study is a multi-centre, blinded, randomized controlled trial. LTCF residents ≥65 years who have had two doses of mRNA-1273 vaccine will be randomized to vaccination with a third dose of mRNA-1273 vaccine or to vaccination with a control (Prevnar-13 vaccine).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Mark Loeb
• Treatments: Heptavalent Pneumococcal Conjugate Vaccine; Vaccines

Criteria

Inclusion Criteria:

• A LTCF resident will be eligible if they are ≥ 65 years and have received two doses of mRNA-1273 vaccine

Exclusion Criteria:

• Immunocompromised individuals due to known or suspected immunodeficiency or due to receipt of immunosuppressive medication (e.g., steroids, biologics)

• Having had a severe adverse reaction (e.g., anaphylactic allergy) to mRNA-1273 or pneumococcal Prevnar-13 vaccine

• Having received pneumococcal polysaccharide vaccine within 12 months.